Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Nelfinavir · Viracept, NSC-747167

Small molecule · Inhibitor of HIV-1 protease · developed by Agouron Pharms

Approved FDA, Mar 1997
1 Registered trials

What is Nelfinavir?

Nelfinavir is a small-molecule inhibitor of HIV-1 protease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Viracept, NSC-747167
Drug type
Small molecule
Targets
HIV-1 protease
Mechanism
Inhibitor of HIV-1 protease
Therapy area
Infectious disease
Developer
Agouron Pharms
In trials of
JSPR
FDA status
Approved as Viracept (March 14, 1997), NDA020778 · FDA label
UNII
HO3OGH5D7I

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 11, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00251030 Phase 4 Healthy Volunteers Completed JSPR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.